• News
    • News by Region
      • College Station
      • Dallas/Fort Worth
      • El Paso
      • Galveston
      • Lubbock
      • San Antonio
      • Texas Cancer News: What You Need to Know
    • News by Topic
      • Alzheimer’s
      • Biofuels
      • Cancer
      • Cardiovascular
      • Diabetes
      • Genetics
      • Infectious Disease
      • Medical Device
      • Neurology
      • Vaccines
    • News by Institution
      • CPRIT
      • Baylor College of Medicine
      • Rice University
      • Texas A&M
      • Texas Heart Institute
      • UNT Health Science Center
      • UT Arlington
      • UT Austin
      • UT Dallas
      • UTHealth
      • UT MD Anderson Cancer Center
      • UT Medical Branch
      • UT Health Science Center San Antonio
      • University of Texas Southwestern Medical Center
    • Editorial Blog
  • Companies
    • Companies by City
      • Austin
        • Featured in Austin
      • College Station
      • Dallas
      • El Paso
      • Fort Worth
      • Galveston
      • Houston
        • Featured in Houston
      • Lubbock
      • San Antonio
      • Temple
      • Waco
    • Companies by Industry
      • Academic/Research
      • Biofuels
      • BioPharm Insurance
      • Biopharma
      • Biotech
      • Clinical Research
      • Contract Research
      • Cosmeceuticals
      • Diagnostics
      • Environmental
      • Featured
      • Genetics
      • Incubator/Accelerator
      • Legal
      • Manufacturing
      • Medical Devices
      • Pharmaceutical
      • Premium
      • Services
      • Supplements
      • Suppliers
      • Venture Capital
  • Service Providers
    • Services
      • Analytical Chemistry
      • Animal
      • Biochemistry
      • Bioprocess Contract
      • Biorepository
      • Cell Biology
      • Cell Culture
      • Chemistry
      • Clinical Research
      • Construction
      • Consulting
      • Contract Manufacturers
      • Contract Pharma
      • Contract Research
    • Suppliers
      • Biospecimens
      • Lab Equipment
      • Manufacturing
      • Meters
      • Microarrays
      • Microscopes
      • Miscellaneous
      • Molecular Biology
      • Packaging
      • Protein
      • Reagents
      • Research Tools
      • RNAi Technology
      • Safety & Hygiene
      • Sample Prep
      • Software Quality
      • Testing Systems
      • Vacuum Equipment
  • Channels
    • Regional Channels
      • Austin
      • College Station
      • Dallas / Fort Worth
      • El Paso
      • Galveston
      • Houston
      • Lubbock
      • San Antonio
    • Topic Channels
      • Alzheimer’s
      • Autism & Autism Spectrum Disorder: What You Need To Know
      • Autosomal Recessive Disease: What You Need To Know
      • Biofuels
      • Biomarkers: What You Need To Know
      • Biomaterials – Biospecimens
      • Brain Cancer: What You Need To Know
      • Cardiovascular
      • Chagas Disease: What You Need To Know
      • Cancer
      • Clostridium Difficile: What You Need To Know
      • Crohn’s Disease: What You Need To Know
      • Cystic Fibrosis: What You Need to Know
      • Dengue Fever: What You Need To Know
      • Depression
      • Ewing’s Sarcoma: What You Need To Know
      • Genetics
      • H7N9: What You Need To Know
      • Hepatitis B: What You Need To Know
      • Infectious Disease
      • Influenza: What You Need To Know
      • Leukemia: What You Need To Know
      • Liver Cancer: What You Need To Know
      • Lung Cancer: What You Need To Know
      • Medical Device
      • Myocardial Ischemia: What You Need To Know
      • Neglected Tropical Diseases: What You Need To Know
      • Neurology
      • Obesity: What You Need To Know
      • Peter Hotez: What You Need To Know
      • Prostate Cancer: What You Need To Know
      • Quantum Dots: What You Need To Know
      • Secondary Progressive MS: What You Need To Know
      • Spinal Muscular Atrophy: What You Need To Know
      • T-Cells: What You Need To Know
      • 3D Technology: What You Need To Know
      • Triple Negative Breast Cancer: What You Need To Know
      • West Nile Virus: What You Need To Know
  • About
  • Advertise

BioNews-TX

BioNews Texas

  • News
    • News by Region
      • College Station
      • Dallas/Fort Worth
      • El Paso
      • Galveston
      • Lubbock
      • San Antonio
      • Texas Cancer News: What You Need to Know
    • News by Topic
      • Alzheimer’s
      • Biofuels
      • Cancer
      • Cardiovascular
      • Diabetes
      • Genetics
      • Infectious Disease
      • Medical Device
      • Neurology
      • Vaccines
    • News by Institution
      • CPRIT
      • Baylor College of Medicine
      • Rice University
      • Texas A&M
      • Texas Heart Institute
      • UNT Health Science Center
      • UT Arlington
      • UT Austin
      • UT Dallas
      • UTHealth
      • UT MD Anderson Cancer Center
      • UT Medical Branch
      • UT Health Science Center San Antonio
      • University of Texas Southwestern Medical Center
    • Editorial Blog
  • Companies
    • Companies by City
      • Austin
        • Featured in Austin
      • College Station
      • Dallas
      • El Paso
      • Fort Worth
      • Galveston
      • Houston
        • Featured in Houston
      • Lubbock
      • San Antonio
      • Temple
      • Waco
    • Companies by Industry
      • Academic/Research
      • Biofuels
      • BioPharm Insurance
      • Biopharma
      • Biotech
      • Clinical Research
      • Contract Research
      • Cosmeceuticals
      • Diagnostics
      • Environmental
      • Featured
      • Genetics
      • Incubator/Accelerator
      • Legal
      • Manufacturing
      • Medical Devices
      • Pharmaceutical
      • Premium
      • Services
      • Supplements
      • Suppliers
      • Venture Capital
  • Service Providers
    • Services
      • Analytical Chemistry
      • Animal
      • Biochemistry
      • Bioprocess Contract
      • Biorepository
      • Cell Biology
      • Cell Culture
      • Chemistry
      • Clinical Research
      • Construction
      • Consulting
      • Contract Manufacturers
      • Contract Pharma
      • Contract Research
    • Suppliers
      • Biospecimens
      • Lab Equipment
      • Manufacturing
      • Meters
      • Microarrays
      • Microscopes
      • Miscellaneous
      • Molecular Biology
      • Packaging
      • Protein
      • Reagents
      • Research Tools
      • RNAi Technology
      • Safety & Hygiene
      • Sample Prep
      • Software Quality
      • Testing Systems
      • Vacuum Equipment
  • Channels
    • Regional Channels
      • Austin
      • College Station
      • Dallas / Fort Worth
      • El Paso
      • Galveston
      • Houston
      • Lubbock
      • San Antonio
    • Topic Channels
      • Alzheimer’s
      • Autism & Autism Spectrum Disorder: What You Need To Know
      • Autosomal Recessive Disease: What You Need To Know
      • Biofuels
      • Biomarkers: What You Need To Know
      • Biomaterials – Biospecimens
      • Brain Cancer: What You Need To Know
      • Cardiovascular
      • Chagas Disease: What You Need To Know
      • Cancer
      • Clostridium Difficile: What You Need To Know
      • Crohn’s Disease: What You Need To Know
      • Cystic Fibrosis: What You Need to Know
      • Dengue Fever: What You Need To Know
      • Depression
      • Ewing’s Sarcoma: What You Need To Know
      • Genetics
      • H7N9: What You Need To Know
      • Hepatitis B: What You Need To Know
      • Infectious Disease
      • Influenza: What You Need To Know
      • Leukemia: What You Need To Know
      • Liver Cancer: What You Need To Know
      • Lung Cancer: What You Need To Know
      • Medical Device
      • Myocardial Ischemia: What You Need To Know
      • Neglected Tropical Diseases: What You Need To Know
      • Neurology
      • Obesity: What You Need To Know
      • Peter Hotez: What You Need To Know
      • Prostate Cancer: What You Need To Know
      • Quantum Dots: What You Need To Know
      • Secondary Progressive MS: What You Need To Know
      • Spinal Muscular Atrophy: What You Need To Know
      • T-Cells: What You Need To Know
      • 3D Technology: What You Need To Know
      • Triple Negative Breast Cancer: What You Need To Know
      • West Nile Virus: What You Need To Know
  • About
  • Advertise
  • Follow
    • Facebook
    • Twitter
    • Google+
    • Linkedin
    • Pinterest
Secondary Progressive MS Research Into Natalizumab Continues To Progress
Home
News

Secondary Progressive MS Research Into Natalizumab Continues To Progress

February 6th, 2014 Mike Nace 0 comments

Natalizumab and secondary progressive msResearchers continue to explore different treatment approaches for secondary progressive MS, ranging from the development of new immunotherapeutic drugs that foster myelin repair and neural protection to immune suppressing drugs that stem the tide of progressive symptoms and advancing debility that typically occurs with the disease. Researchers at the Collaborative MS Research Center at the University of California at San Francisco are working on several different treatment approaches, as well as seeking to develop molecules that may be used as biomarkers to help doctors predict MS progression before it occurs.

However, for those MS patients who have already been diagnosed with secondary progressive MS, the Center’s research into use of the drug Natalizumab may offer particular hope for a definitive treatment for the disease.

Find out more about secondary progressive MS.

The current study involving Natalizumab seeks to determine whether the drug is particularly efficacious in reducing the progression of disability for patients who already have secondary progressive MS. It is a relatively large study involving 156 different site locations throughout the world, and the fact that the study is Phase 3b suggests that the use of the drug in treating SPMS has shown enough success in previous studies to be cleared for testing across a wide range of participants.

The study will use a randomized, double-blind, placebo-controlled approach for approximately 856 SPMS subjects whose disease has clearly progressed to the point where symptoms no long come in waves, but are sustained — the defining feature of secondary progressive MS.  The participants in the study will be randomized to receive either natalizumab 300 mg or placebo intravenously (IV) every 4 weeks (q4wk) for 96 weeks, and participants must be between the ages of 18 and 58, inclusive, with a diagnosis of SPMS for at least 2 years, an EDSS score between 3.0 and 6.5, inclusive, and documented evidence of disease progression independent of clinical relapses over the 1 year prior to enrollment, and who are naïve to Natalizumab.

 

In point of fact, while Natalizumab may not be commonly known in the MS community — to date, it has generally been used only as a last-resort medication for non-relapsing patients who have tried other drugs to no avail –it is used to treat Crohn’s disease as well. The reason for this is that, while the drug was initially approved by the FDA in 2004, was approved in 2004 after many years of testing, the drug was later linked in three cases of the rare neurological condition progressive multifocal leukoencephalopathy (PML) when administered in combination with interferon beta-1a. Because interferon is typically used as an MS treatment option, the drug was pulled from the market. In this way, Natalizumab has offered middling results, much in the same way that most drugs do during their clinical trials.

The most recent clinical work done on the drug involving secondary progressive MS, however, has been promising. An article in MedScape from 2012 revealed promising results for Natalizumab in progressive MS, with the drug’s Phase 2 study revealing that the drug (this study used the Natalizumab brand Tysabri, from Biogen Idec) reduced inflammation, axonal damage, and demyelination in patients with progressive multiple sclerosis (MS). This was a particularly important study, since inflammation, axonal damage, and myelin repair are all key elements to what will eventually lead to a successful treatment option for secondary progressive MS.

despite the new late-phase study for Natalizumab, the drug undoubtedly has farther to go before it can be claimed as a true breakthrough treatment for SPMS. However, in spite of a few setbacks in testing, the DFA and research community still consider the drug to be a viable option.

[divider]



Share this article

Next article MD Anderson a Thought Leader in Intelligent Redesign of Cancer Care Delivery
Previous article Cystic Fibrosis Foundation's Fundraising Efforts Fueled By Local Advocacy

Mike Nace

Mike Nace is the Editor-in-Chief of BioNewsTexas. He regularly covers corporate and political news pertaining to the Texas biotech sector.

Popular Tags

20th annual Vulcan Materials Funshoot 340B 2014 World Stem Cell Summit austin BIG DATA bioaustin biorepositories biospecimens blog Cancer Therapy & Research Center Chemistry Chuck Reed College Station CPRIT CPRIT Foundation crowdfunding cystic fibrosis Dallas DFW drug discount enventure fort worth Funding Galveston GlaxoSmithKline Governor Rick Perry Greatbatch Greg Abbott Health Industry Council of North Texas houston How to Support People With MS Jennifer Stevens lab Medical Device Multiple Sclerosis Multiple Sclerosis Support Obama Obamacare Primary Progressive Multiple Sclerosis san antonio Sante Ventures SB 149 Signs Of MS Texas A&M thbi

Archives

  • Texas’ Only Source For Biotech & Life Sciences News
  • About
  • News
  • Terms of Use
  • Privacy Policy
  • Contact
  • Back to top
© BioNews Services
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more